Modulation of endometrial transforming growth factor beta (TGFbeta) by tamoxifen.
Transforming growth factor beta (TGFbeta) immunoreactivity was determined in endometria from non-drug-therapy and tamoxifen-treated patients. Sections were scored for pathology and quantity image analysis performed to determine levels of glandular- or fibrosis-associated TGFbeta1. Tamoxifen-treated patients displayed greater levels of endometrial dysplasia and glandular hyperplasia, in addition to a statistically significant (P<0.0001) elevation in gland-associated TGFbeta1 protein.
Carmichael
P L
PL
Imperial College School of Medicine, Molecular Toxicology, Sir Alexander Fleming Building, South Kensington, SW7 2AZ, London, UK. p.carmichael@ic.ac.uk
Pole
J C
JC
Neven
P
P
D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D016889:Endometrial Neoplasms / Q000139:chemically induced* / Q000378:metabolism; D004717:Endometrium / Q000187:drug effects / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D013629:Tamoxifen / Q000009:adverse effects / Q000494:pharmacology*; D016212:Transforming Growth Factor beta / Q000378:metabolism*
D018931:Antineoplastic Agents, Hormonal; D016212:Transforming Growth Factor beta; D013629:Tamoxifen